News
Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed ...
14h
Zacks Investment Research on MSNCompany News for Jul 9, 2025U.S-based copper mining company Freeport-McMoRan Inc. FCX gained 2.5% on Trump’s tariff threats on imported copper. Shares of Moderna, Inc. MRNA gained 8.8% on leading medical organizations filing a ...
Trump administration policy tug-of-war between big medical groups that want COVID vaccines back on CDC schedule for healthy kids and pregnant women, groups that want mandate ban extended to health ...
The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and ...
1d
Barchart on MSNThe Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...
The U.S. Centers for Disease Control and Prevention ended its emergency response for bird flu as the outbreak that sickened ...
The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.
The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...
We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results